A useful marker for detecting minimal residual disease (MRD) has not been established yet in retinoblastoma. We assessed neuroendocrine protein gene product 9.5 (PGP9.5) expression, one of the markers for detecting MRD in neuroblastoma, in a patient with disseminated retinoblastoma. A 3-year-old boy with disseminated retinoblastoma in multiple bones and marrow was referred to our hospital. He received intensive treatment and has maintained CR for 48 months following myeloablative chemotherapy with hematopoietic stem cell transplantation (SCT). PGP9.5 expression was serially assessed by RT-PCR in peripheral blood mononuclear cells (PBMC), bone marrow cells (BMC) and mobilized peripheral blood stem cells (PBSC). Initially, his BMC consisted of 96% tumor cells which were proved to express PGP9.5 by RT-PCR. Moreover, PBMC were found to be positive for PGP9.5 indicating the presence of tumor cells in the peripheral blood. After intensive chemotherapy, PGP9.5 expression became negative in both PBMC and BMC. Prior to SCT, PBSC and BMC transplants were confirmed negative for PGP9.5 expression. It is suggested that PGP9.5 expression is a useful marker for evaluating therapeutic effects as well as detecting MRD in retinoblastoma. Keywords: minimal residual disease; myeloablative chemotherapy; neuroendocrine protein gene product 9.5; retinoblastoma; stem cell transplantation Prognosis of extraocular retinoblastoma (RB) has remained relatively poor for both orbital and distant metastatic diseases.
Prognosis of extraocular retinoblastoma (RB) has remained relatively poor for both orbital and distant metastatic diseases. 1 High-dose chemotherapy with or without BM rescue has reportedly demonstrated curative responses in patients with metastatic RB. 1, 2 Generally, it is suggested that residual tumor cells in the BM show clonogenic growth in vitro and contribute to disease recurrence. 3 Therefore, sensitive detection and effecCorrespondence: Dr T Matsumura, Department of Pediatrics, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyoku, Kyoto 602-8566, Japan Received 5 October 1998; accepted 2 December 1998 tive eradication of minimal residual disease (MRD) in transplants are important for hematopoietic stem cell transplantation (SCT). 4 Useful markers for detecting MRD have been established in a variety of tumors, but not yet in RB. Neuroendocrine protein gene product 9.5 (PGP9.5) originally expressed in the neuroendocrine tissues has been used as a marker for detecting MRD in neuroblastoma (NB). 5 Since RB originates from neural crest cells as does NB, 6 PGP9.5 is a candidate for a useful as well as a practical marker for detecting MRD in RB.
We report here a boy with RB which recurred with metastases in multiple bones and in the marrow. He has maintained CR for 48 months after intensive chemotherapy followed by myeloablative chemotherapy with SCT. We assessed PGP9.5 expression in his PBMC, BMC and PBSC by RT-PCR, and demonstrated that the expression could be a useful marker for detecting MRD in RB.
Case report

Clinical presentation
A boy, born 13 July 1990, was noticed with leukocoria at the age of 15 months, and was diagnosed as bilateral RB. None of his relatives has suffered from RB. Since his right eye was extensively involved with tumor, the enucleation of the right eye was performed at a referred hospital. The histopathological diagnosis was RB with pT3b in TMN classified system. His left eye's 12 mm diameter tumor was successfully treated with irradiation and photocoagulation. At the age of 21 months his RB recurred with a 2 mm diameter tumor in the left eye. He received laser beam therapy combined with intravenous carboplatinum (CBDCA). When the RB recurred again in the left eye at the age of 30 months, the left eye was enucleated. The histopathological diagnosis was RB with pT3c in the TMN classified system. However, at the age of 38 months, two subcutaneous tumors in the right side of the head and the swelling of the left eyelid were noticed. Two months later, he was referred to our hospital.
The laboratory data at presentation were as follows: serum AST, LDH and CPK levels were high up to 96 IU/l, 4848 IU/l and 215 IU/l, respectively. As with the tumor markers, the serum NSE level increased to 660 ng/ml. The cerebrospinal fluid was chemically and cytologically normal. BMC obtained from the iliac bone consisted of 96% abnormal blasts, which generated the rosette formation of Flexner-Wintersteiner type. Bone scintigraphy showed abnormal uptakes in the right-side of the skull, the left tibia, the left femur and the left side of the lumbar spine. Contrast-enhanced CT showed a tumor with calcification in the left orbit and tumors in the right temporal and parietal bones. No lesions were detected in the brain.
Treatment and follow-up (Figure 1)
According to the protocol of Grabowski and Abramson, 7 he received an alternate combination chemotherapy consisting of adriamycin (ADR), VCR and CY, and of cisplatin (CDDP) and etoposide (VP16). Although serum LDH, CPK and NSE levels and the frequency of abnormal cells in the BM decreased following a single cycle of this combination, metastatic tumors on the skull increased in size. Thereafter, he was treated with a combination chemotherapy consisting of CY, CDDP, tetrahydropyranyl adriamycin (THP-ADR) and VP16 which is a protocol for NB by the Study Group of Japan. 8 After two courses, good response was achieved and VP16 was discontinued because of concerns about an increased risk of secondary malignancy in bilateral RB. For future SCT, PBSC were collected three times during sequential chemotherapy. Additionally, autologous BMC were also collected and stored for backup marrow.
Finally, myeloablative chemotherapy followed by SCT was carried out on 27 October 1994, 13 months after starting induction chemotherapy. SCT-preconditioning regimen consisted of CBDCA 400 mg/m 2 once daily continuous d.i.v. on days Ϫ7, Ϫ6, Ϫ5 and Ϫ4 (total dose 1600 mg/m , prednisolone 10 mg). The transplants contained 2 ϫ 10 5 colony-forming units granulocyte-macrophage (CFU-GM)/kg in PBSC from the second and the third collections and 1 ϫ 10 5 CFU-GM/kg in autologous BMC, all of which were prospectively proved to have no PGP9.5 expression. He has, so far, maintained CR for 48 months after SCT. Moreover, at 6, 9, 12, 24 and 48 months after SCT, his BMC were confirmed to be negative for PGP9.5 expression (data not shown).
Detection of PGP 9.5 PGP9.5 expression was assessed by RT-PCR in PBMC, BMC and PBSC samples taken serially from the patient. PBMC from a healthy volunteer and a RB cell line, Y79, served as a negative and a positive control for PGP9.5, respectively.
RNA and cDNA preparation
Total RNA was extracted from BMC, PBSC, PBMC and cultured RB cells using an acid-guanidinium thiocyanatephenol-chloroform (AGPC) method. 9 Single-stranded cDNA synthesis from a 25 g sample of template RNA with oligo dT (12-18) (Pharmacia P-L Biochemical, Milwaukee, WI, USA) was performed using reverse transcriptase isolated from Avian Myeloblastosis Virus (Life Science, St Petersburg, FL, USA). After extraction of cDNA with phenol-chloroform, cDNA was resuspended in water.
PCR
RT-PCR amplification of cDNA with corresponding 2.5 g RNA was performed in a 50 l reaction mixture containing 10 mm Tris, 50 mm KCl, 200 m each of 4 deoxyribonucleotide 5Ј triphosphates, 0.2 m each of primers and 1 U Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA). The primer sequences for PCR amplification for PGP 9.5 were 5Ј-AGA TCA ACC CCG AGA TGC TGA ACA AAG TGC TG-3Ј and 5Ј-ATT AGG CTG CCT TGC AGA GAG CCA CGG CAG AGA A-3Ј. 5 Amplification was performed for 35 cycles (40 s at 94°C, 75 s at 72°C) and analyses of PCR products were performed with a 2% agarose gel electrophoresis. ␤-actin served as an internal control.
Results
PGP9
.5 expression in serial samples including PBMC, BMC and PBSC are shown in Figure 2 . PBMC (PB) and BMC (Bm ) specimens obtained on admission and the initial PBSC (PBSC ) showed positive expression of PGP9.5. After sequential chemotherapy, the expression became negative in all types of samples, suggesting a good response to induction chemotherapy. Autologous BMC collected for backup marrow were found negative for PGP9.5 expression (data not shown). These results and the clinical course of our patient suggest that PGP9.5 expression is a predictable and a useful marker not only for detecting MRD but also for evaluating therapeutic effects.
Discussion
The prognosis of extraocular RB remains relatively poor for both orbital and distant metastatic diseases, 1 although myeloablative chemotherapy with or without SCT 1,2 has brought about curative effects in some patients with disseminated RB. In SCT, however, residual malignant cells in the graft were found to be capable of clonogenic growth in vitro and, further, to be responsible for subsequent relapse in vivo. 10 Whereas a sensitive detection of MRD in collected cells for SCT has been explored in a variety of cancers, 4 a reliable marker for MRD detection has not yet been established in RB.
PGP9.5 is exclusively expressed in the nervous system, but not in normal BMC, PMNC or PBSC.
5,11 Furthermore, we have confirmed that hematopoietic cells from 10 healthy children express no PGP9.5 by RT-PCR. 11 Additionally, by using this marker, a minimal contamination of neurogenic cells into BMC and PBMC could have been detected at a sensitivity of 1/10 7 , so that it has been applied to the detection of MRD in NB. 5, 11 Since RB originates from neural crest cells as does NB, 6 it is suggested that PGP9.5 expression could be a useful as well as a practical marker for detecting minimal contamination of RB cells in PBMC, BMC and PBSC. We have done preliminary experiments and found that a RB cell line, Y79, expressed PGP9.5. Indeed, at diagnosis of BM involvement, our patient's BMC containing 96% abnormal cells expressed PGP9.5. Following intensive chemotherapy, his BMC were cleared of its expression, suggesting total eradication of metastatic cells in BM. Thus, our observation suggested that PGP9.5 is a useful marker for detecting MRD in RB as well.
Although it remains unclear whether MRD in the graft contributes to clinical recurrence afterwards, we tried to avoid the use of PBSC which were positive for PGP9.5 expression. Since the cryopreserved PBSC which were negative for the expression contained a minimum amount of CFU-GM for SCT, preserved autologous BMC negative for PGP9.5 expression were combined with PBSC for transfusion. Compared with autologous BMC, tumor cell contamination would be expected to be generally less frequent in PBSC. 12 Therefore, PBSC without the evidence of MRD would be the most reliable graft for SCT. Our patient has, so far, remained in CR for 48 months after myeloablative chemotherapy followed by transplantation of PBSC and BMC with no PGP9.5 expression. In this respect, molecular detection of MRD by using PGP9.5 is a predictable as well as a useful tool in disseminated RB for ascertaining the safety of SCT.
